MK-3682C
Total Payments
$1.7M
Transactions
52
Doctors
1
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $8,500 | 31 | 1 |
| 2017 | $1.7M | 21 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.7M | 52 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Four-Part Study to Evaluate the Drug-Drug Interaction of MK-3682C with Genvoya, Darunavir,Ritonavir, Atazanavir,Ritonavir, and Atripla in Healthy Subjects | Merck Sharp & Dohme Corporation | $1.2M | 0 |
| An open-label, single-dose study to evaluate the pharmacokinetics of two conventional formulations of MK-3682C, high-strength, in healthy adult subjects | Merck Sharp & Dohme Corporation | $492,592 | 0 |
| An open-label, single-dose study to evaluate the pharmacokinetics of an enabled formulation of MK-3682C, high-strength, in healthy adult subjects | Merck Sharp & Dohme Corporation | $28,269 | 0 |
| A Phase 3 Clinical Study to Evaluate the Efficacy and Safety of the Combination Regimen of MK-3682C Ruzasvir,Uprifosbuvir in Participants with Chronic Hepatitis C Virus Genotype 1 or 4 Infection | Merck Sharp & Dohme Corporation | $6,300 | 1 |
| MK-3682C Ruzasvir,Uprifosbuvir in HCV GT2 | Merck Sharp & Dohme Corporation | $3,800 | 1 |
Top Doctors Receiving Payments for MK-3682C
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Lincoln, NE | $1.7M | 50 |
| , MD | Gastroenterology | Cleveland, OH | $400.00 | 2 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $1.7M
- Total Doctors 1
- Transactions 52
About MK-3682C
MK-3682C is a drug associated with $1.7M in payments to 1 healthcare providers, recorded across 52 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2017 to 2018. In 2018, $8,500 was paid across 31 transactions to 1 doctors.
The most common payment nature for MK-3682C is "Unspecified" ($1.7M, 100.0% of total).
MK-3682C is associated with 5 research studies, including "A Four-Part Study to Evaluate the Drug-Drug Interaction of MK-3682C with Genvoya, Darunavir,Ritonavir, Atazanavir,Ritonavir, and Atripla in Healthy Subjects" ($1.2M).